Ignite Creation Date:
2025-12-25 @ 4:32 AM
Ignite Modification Date:
2026-01-07 @ 1:54 PM
Study NCT ID:
NCT06308718
Status:
TERMINATED
Last Update Posted:
2025-09-05
First Post:
2024-03-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007965', 'term': 'Leukodystrophy, Globoid Cell'}, {'id': 'D016464', 'term': 'Lysosomal Storage Diseases'}], 'ancestors': [{'id': 'D020279', 'term': 'Hereditary Central Nervous System Demyelinating Diseases'}, {'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D013106', 'term': 'Sphingolipidoses'}, {'id': 'D020140', 'term': 'Lysosomal Storage Diseases, Nervous System'}, {'id': 'D056784', 'term': 'Leukoencephalopathies'}, {'id': 'D003711', 'term': 'Demyelinating Diseases'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008064', 'term': 'Lipidoses'}, {'id': 'D008052', 'term': 'Lipid Metabolism, Inborn Errors'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Whole Blood, Peripheral Blood Mononuclear Cells, Plasma, Urine, Faces, Saliva.'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 2}, 'patientRegistry': False}, 'statusModule': {'whyStopped': 'The FBX-101 clinical program has been discontinued by Forge Biologics', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2024-08-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2025-04-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-08-29', 'studyFirstSubmitDate': '2024-03-06', 'studyFirstSubmitQcDate': '2024-03-12', 'lastUpdatePostDateStruct': {'date': '2025-09-05', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-03-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-04-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Long Term safety as assessed by incidence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) that are attributed to FBX-101', 'timeFrame': '36 months'}], 'secondaryOutcomes': [{'measure': 'Efficacy as assessed by change of gross motor function measured longitudinally by Peabody Developmental Motor Scale (PDMS-2)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of gross motor function measured longitudinally by Bruininks-Oseretsky Test of Motor Proficiency (BOT-2)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of gross motor function measured longitudinally by Gross Motor Function Measure 88 (GMFM-88)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of fine motor function measured longitudinally by Mullen Scales of Early Learning (MSEL)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of fine motor function measured longitudinally by Beery VMI Sixth Edition (VMI)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of fine motor function measured longitudinally by Bayley Scales of Infant Development (Bayley-III)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of fine motor function measured longitudinally by Vineland Adaptive Behavior Scale (Vineland 3)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of cognitive function measured longitudinally by Mullen Scales of Early Learning (MSEL)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of cognitive function measured longitudinally by the Differential Ability Scale II (DAS-II)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of cognitive function measured longitudinally by Bayley Scales of Infant Development (Bayley-III)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of adaptive behaviour function measured longitudinally by Vineland Adaptive Behavior Scale (Vineland 3).', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of language function measured longitudinally by Mullen Scales of Early Learning (MSEL).', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of language function measured longitudinally by Clinical Evaluation of Language Fundamentals Fifth Edition (CELF-5)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of language function measured longitudinally by Bayley Scales of Infant Development (Bayley-III)', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of language function measured longitudinally by Vineland Adaptive Behavior Scale (Vineland 3).', 'timeFrame': '36 months', 'description': 'The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.'}, {'measure': 'Efficacy as assessed by change of quality of life measured longitudinally by the Pediatric Quality of Life (PedsQL) Generic Core Scales with Family Impact Module and Multidimensional Fatigue Scale', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of developmental milestones such as language and motor skills as measured longitudinally by an specific Developmental Milestones questionnaire', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of hearing function measured longitudinally by Auditory Brainstem Responses (ABRs)', 'timeFrame': '36 months', 'description': 'Absolute values for Waves I, III and V in milliseconds will be recorded along interpretation and waveform morphology; and also Auditory Brainstem Responses (corrected).'}, {'measure': 'Efficacy as assessed by change of hearing function measured longitudinally by Behavior Audiometry (BAUD)', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of peripheral nerve conduction velocity measured longitudinally by Nerve Conduction Velocity (NCV) assessments', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of Fractional Anisotropy (FA) as measured longitudinally by brain Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of visual function as measured longitudinally by visual evoked potentials (VEP)', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of visual function as measured longitudinally by visual acuity', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of whole blood donor chimerism', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of psychosine in whole blood and plasma', 'timeFrame': '36 months'}, {'measure': 'Efficacy as assessed by change of Galactosylceramidase (GALC) levels in plasma and Cerebrospinal Fluid (CSF)', 'timeFrame': '36 months'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Lysosomal Storage Disorder', 'Globoid Cell Leukodystrophy', 'Leukodystrophy', 'GALC'], 'conditions': ['Krabbe Disease']}, 'referencesModule': {'references': [{'pmid': '30089515', 'type': 'BACKGROUND', 'citation': 'Bascou N, DeRenzo A, Poe MD, Escolar ML. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. Orphanet J Rare Dis. 2018 Aug 9;13(1):126. doi: 10.1186/s13023-018-0872-9.'}, {'pmid': '30777126', 'type': 'BACKGROUND', 'citation': 'Beltran-Quintero ML, Bascou NA, Poe MD, Wenger DA, Saavedra-Matiz CA, Nichols MJ, Escolar ML. Early progression of Krabbe disease in patients with symptom onset between 0 and 5 months. Orphanet J Rare Dis. 2019 Feb 18;14(1):46. doi: 10.1186/s13023-019-1018-4.'}, {'pmid': '15901860', 'type': 'BACKGROUND', 'citation': "Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, Wenger DA, Pietryga D, Wall D, Champagne M, Morse R, Krivit W, Kurtzberg J. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005 May 19;352(20):2069-81. doi: 10.1056/NEJMoa042604."}, {'pmid': '33150395', 'type': 'BACKGROUND', 'citation': 'Yoon IC, Bascou NA, Poe MD, Szabolcs P, Escolar ML. Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease. Blood. 2021 Apr 1;137(13):1719-1730. doi: 10.1182/blood.2020005477.'}, {'pmid': '28855403', 'type': 'BACKGROUND', 'citation': 'Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study. Neurology. 2017 Sep 26;89(13):1365-1372. doi: 10.1212/WNL.0000000000004418. Epub 2017 Aug 30.'}, {'pmid': '25844309', 'type': 'BACKGROUND', 'citation': 'Gupta A, Poe MD, Styner MA, Panigrahy A, Escolar ML. Regional differences in fiber tractography predict neurodevelopmental outcomes in neonates with infantile Krabbe disease. Neuroimage Clin. 2014 Sep 26;7:792-8. doi: 10.1016/j.nicl.2014.09.014. eCollection 2015.'}, {'pmid': '37952085', 'type': 'BACKGROUND', 'citation': 'Bradbury AM, Bagel J, Swain G, Miyadera K, Pesayco JP, Assenmacher CA, Brisson B, Hendricks I, Wang XH, Herbst Z, Pyne N, Odonnell P, Shelton GD, Gelb M, Hackett N, Szabolcs P, Vite CH, Escolar M. Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy. Mol Ther. 2024 Jan 3;32(1):44-58. doi: 10.1016/j.ymthe.2023.11.014. Epub 2023 Nov 11.'}, {'pmid': '16864820', 'type': 'BACKGROUND', 'citation': 'Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: effect of hematopoietic stem cell transplantation. Neurology. 2006 Jul 25;67(2):268-72. doi: 10.1212/01.wnl.0000230156.01228.33.'}, {'pmid': '32634238', 'type': 'BACKGROUND', 'citation': 'Vander Lugt MT, Chen X, Escolar ML, Carella BA, Barnum JL, Windreich RM, Hill MJ, Poe M, Marsh RA, Stanczak H, Stenger EO, Szabolcs P. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020 Jul 14;4(13):3041-3052. doi: 10.1182/bloodadvances.2020001940.'}]}, 'descriptionModule': {'briefSummary': 'This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.', 'detailedDescription': 'FBX-101-LTFU is a multicenter, non-interventional, Long-Term Follow-Up (LTFU) study of participants from prior interventional trials involving the administration of FBX-101. Eligible participants will undergo clinical evaluations at prespecified intervals for at least 3 years from the last visit in the prior clinical trial (up to 5 years post-FBX-101 treatment). Overall safety and additional signs of efficacy will be collected with a series of laboratory tests, diagnostic tests, and performance surveys. Additionally, children participating in interventional trials that are terminated early will be transferred to this LTFU study and will complete any pending visits from the interventional trial before starting the clinical evaluations included in this protocol.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'This is an observational long-term follow-up (LTFU) study of participants from prior interventional trials involving the administration of FBX-101.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Participants that have completed a prior clinical trial involving the administration of FBX-101.\n* Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule.\n\nExclusion Criteria:\n\n•Planned or current participation in any other interventional clinical study that may confound the safety or efficacy evaluation of FBX-101 during this study.'}, 'identificationModule': {'nctId': 'NCT06308718', 'briefTitle': 'Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients', 'organization': {'class': 'INDUSTRY', 'fullName': 'Forge Biologics, Inc'}, 'officialTitle': 'A Long-term Follow-up Study to Evaluate Safety and Efficacy of Krabbe Patients From Gene Therapy Clinical Trials Involving the Administration of FBX-101 (AAVrh.10-hGALC)', 'orgStudyIdInfo': {'id': 'FBX-101-LTFU'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients enrolled in the FBX-101-LTFU study', 'description': 'The participants will be followed for 36 months after they have concluded their participation in the interventional trial. They will complete 5 scheduled visits with assessments as specified in the schedule of assessments, to collect data for safety and additional signs of efficacy for FBX-101. Those patients enrolled from any other early terminated trial, will first complete pending evaluations from that trial.', 'interventionNames': ['Biological: FBX-101']}], 'interventions': [{'name': 'FBX-101', 'type': 'BIOLOGICAL', 'description': 'A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.', 'armGroupLabels': ['Patients enrolled in the FBX-101-LTFU study']}]}, 'contactsLocationsModule': {'locations': [{'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan Hospitals - Michigan Medicine', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Forge Biologics, Inc', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}